Individualizing Apheresis Processing Volumes Using a Predictive Algorithm: Analysis of the CAR T-Cell Collection Protocol Utilized in ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL.

What was studied

This study looked at a plan for collecting T cells. The T cells are used to make CAR T-cell therapy. The plan sets how much blood to process. The usual practice may process more blood than needed. The team made a protocol with a first estimate. It adjusts the estimate at the midpoint. It was part of the ACIT001/EXC002 trial in relapsed or refractory lymphoma or leukemia.

What they found

The first estimate was adequate or conservative in a high share of procedures. Many patients needed less blood processing than the usual amount. The target T-cell yield was reached in a high share of patients.

What it means for patients

The authors say the midpoint-adjusted plan can cut unneeded time on the machine. They say it keeps T-cell collection reliable. They say it may improve use of resources and patient safety.

Why it is not certain yet

The abstract does not give how many patients were studied. It reports no comparison with other collection methods. It describes one protocol within a single trial.

Source

Individualizing Apheresis Processing Volumes Using a Predictive Algorithm: Analysis of the CAR T-Cell Collection Protocol Utilized in ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL.

We restate facts from the source record in our own words. The original wording belongs to its publisher.